Medigene
Business Services · Germany · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Lochhamer St 11, Planegg, Bavaria, 82152...Phone Number
+49 892000330Website
www.medigene.comRevenue
$8.2 MillionStock Symbol
MDG1Industry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Medigene
Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies such as T cell receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer in fields of high medical need. The first product candidates are in clinical development.Explore more
Medigene Org Chart
TT
Senior Sales Manager
MB
Manager
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medigene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Medigene has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Medigene launches new products
Medigene, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Medigene is spiking on competitors!
Check if Medigene has recently received funding, and reach out quickly before it becomes old news!
Click to see if Medigene had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Medigene recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Medigene
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Medigene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Medigene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Medigene.
Medigene financials insights
Gather financial insights about Medigene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$117.7M
Medigene Tech Stack
A closer look at the technologies used by Medigene
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Lateral Move
Executive Move
Executive Moves, Lateral Move
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Medigene News & Media
PTA-Adhoc: Medigene AG: Departure of Chief Executive Officer Dr. Selwyn Ho and ... - TradingView
Medigene AGby Medigene PR/IRPublic disclosure of inside information according to article 17 MAR Planegg/Martinsried (pta/18.07.2025/16:00) - Medigene AG (FWB: MDG1, General Standard) announces that Chief Executive Officer (CEO) Dr. Selwyn Ho will leave the Company upon the expiration of his regular…Medigene Files Patent for Unique NK-Specific TCR Construct with European Patent Office
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today announced the submission of a patent for a novel natural killer (NK) cell-specific TCR construct to the European Patent Office. With that, Medigene is advancing its TCR-guided strategy by expanding the application of its proprietary 3S (sensitive, specific, and safe) TCRs into NK cells. This patentMedigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.Medigene AG Expands Patent Portfolio with Patent Grant for its JOVI Technology in the U.S.
Planegg/Martinsried, February 19, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced today that the Company has been issued a patent by the U.S. Patent Office protecting its JOVI technology, a method allowing the enrichment of T cells using a specific anti-Cβ antibody. The U.S. patent for the JOVI technology was granted at
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Medigene
Sign Up For FreeTo access detailed company insights
Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies such as T cell receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer in fields of high medical need. The first product... Read More
